Reduced intensity conditioning (RIC) for allogeneic stem cell transplantation allows stable donor cell engraftment with the maintenance of a graft versus malignancy effect. Many different regimens exist employing various combinations of chemotherapy, radiotherapy and T-cell depletion. We examined the role of non-T-cell depleted RIC regimens in 56 patients with haematological malignancies. Patients received fludarabine phosphate for 5 days (30 mg/m 2 in 35 patients, 25 mg/m 2 in 21 patients) and melphalan for 1 day (140 mg/m 2 in 36 patients, 100 mg/m 2 in 20 patients). Immunosuppression was with CyA alone in 33 patients and CyA/MTX in 23 patients. Twenty-four of the 26 patients with chimerism data showed 495% donor chimerism at 3 months post transplant. aGVHD occurred in 18% of patients receiving CyA/MTX compared to 53% of patients receiving CyA. The 100-day mortality rate was 0.16 (95%CI 0.08-0.28) and 1-year nonrelapse mortality was 0.24 (95%CI 0.13-0.38). Thirty-three patients remained alive and in CR at a median of 19 months post transplant (range 3-38 months). We have shown that patients transplanted with fludarabine phosphate, melphalan 100 mg/m 2 and with CyA/MTX as post transplant immunosuppression can achieve good disease control with an acceptable level of toxicity. Further studies are required to confirm these findings.
Introduction
Reduced intensity conditioning (RIC) regimens have allowed the potential benefits of a graft versus malignancy effect to be offered to an older and less fit population than standard dose conditioning regimens would allow. 1, 2 However, despite the reduced intensity of the conditioning, rates of graft-versus-host disease (GvHD) and transplantrelated mortality can be comparable to those seen following fully myeloablative transplants. 3, 4 Over 30 different RIC regimens have been reported in the literature using a variety of chemotherapy, radiotherapy and GvHD prophylaxis regimens. 5 The majority of current regimens use fludarabine phosphate in combination with another myelosuppressive chemotherapeutic agent or low dose total body irradiation. Regimens have been classified according to the degree of myelosuppression and immunosuppression that they induce. 6 These differences have been shown to influence the kinetics of engraftment and response. [7] [8] [9] [10] [11] The combination of fludarabine phosphate with melphalan (Flu/Mel) in RIC regimens is a moderately intensive regimen. 1, 2, 6 When compared to less myelosuppressive RIC regimens this combination has been associated with a faster time to full donor chimerism, less graft rejection, lower relapse rates and, in some studies, improved overall survival. 7, 12 This, however, has been at the expense of increased rates of GvHD and increased transplant-related mortality (TRM) and morbidity. Early studies with the Flu/Mel combination employed melphalan doses of 140 mg/m 2 (MEL140) to 180 mg/m 2 (MEL180). 1, [13] [14] [15] The rates of GvHD in these studies were comparable to those seen following myeloablative conditioning regimens. A particular problem was high rates of mucositis especially when melphalan was combined with MTX as GvHD prophylaxis. 16, 17 Rates of GvHD following RIC regimens are influenced by the post transplant immunosuppression used. The combination of Flu/Mel140 with Cyclosporin alone as post transplant immunosuppression has been shown in one small study to result in acute GvHD (aGvHD) in 40% of patients with this rising to 70% post prophylactic DLI. 18 The addition of methotrexate or tacrolimus to CyA in post transplant immunosuppression has been associated with a lower but still significant rate of aGvHD of 0-43%. 14, 15, [19] [20] [21] [22] Furthermore the use of antithymocyte globulin (ATG) or alemtuzumab (Campath), has been associated with less aGvHD 23, 24 but with an increased risk of delayed donor chimerism, increased use of donor leukocyte infusions, increased risk of relapse and increased infectious complications when compared to non-T-cell depleted regimens. 25, 26 A comparative casecontrolled nonrandomised study comparing a Flu/Mel regimen employing CyA/MTX or alemtuzumab immunosuppression showed reduced aGvHD in the alemtuzumab group, but an increased relapse rate and no significant difference in overall survival between the two populations. 26 Thus a reduction in aGvHD can be achieved but at the potential expense of disease control. This has been particularly shown in patients with acute leukaemia or relapsed/refractory disease at the time of transplantation. To further investigate the role of non-T cell depleted Flu/Mel based conditioning regimens, we have studied a series of 56 patients who have been treated with this regimen, employing two different doses of melphalan and different post transplant immunosuppression regimens.
Patients and methods

Patient population and demographics
Data were collected on 56 patients transplanted from January 1999 to November 2002. All patients had haematological malignancies known to be susceptible to a graftversus-disease effect and were considered unsuitable for a standard conditioned stem cell transplant (23 on the basis of age alone, six due to age and comorbid conditions, one due to age and previous treatment, nine due to comorbid conditions alone, six due to previous treatment, 10 due to disease subtype where a conventional allograft was not deemed appropriate, and one due to patient choice). Thirteen patients were enrolled prospectively in a phase II clinical trial assessing the safety and efficacy of a non-T-cell depleted nonmyeloablative stem cell transplant conditioning regimen (patient numbers 44-56, see Tables 1 and 2 ). Data were also retrospectively collected on a further 43 patients concurrently treated at the research sites with a similar conditioning regimen but not registered on the trial protocol. Most nontrial patients had haematological malignancies that would have excluded them from entry into the clinical study. Study patients were to have received filgrastim (5 mcg/ kg/day) from day þ 1 until neutrophil recovery, for a maximum of 28 days. The use of GCSF in off-study patients was according to local practice. Patients receiving FLU/MEL100/CyA/MTX did not receive growth factor support following conditioning.
Conditioning and GvHD prophylaxis
Data collection and statistical analysis
Post transplant data were collected including time to neutrophil and platelet recovery, defined as neutrophils 40.5 Â 10 9 /l and platelets 420 Â 10 9 /l, respectively, length of stay in hospital, incidence and grade of aGvHD and cGvHD, incidence of cytomegalovirus (CMV) reactivation, time to donor engraftment, use of donor leukocyte infusions (DLI), day 100 mortality and disease response. Chimerism analysis was performed according to local protocols. Available data on the local assessment of disease response/status at 3 months post transplant were collected and summarized.
Variables were summarized using standard summary statistics applicable to the nature of the data, quantitative or qualitative. All available data were used when summarizing the variables of interest without applying any imputation techniques for missing data. The overall survival (OS) and progression free survival (PFS) were summarized using Kaplan-Meier survival methods. Survival time was defined as the time from the date of patient registration to the date of death with surviving patients being censored on the date on which they were last known to be alive. PFS was defined as the time from the date of patient registration to the date of death or progression of disease with a patient being censored on the date on which they were last known to be alive and progression free.
Patient characteristics
Patient characteristics are detailed in Table 1 . In summary, the median age of the patients at time of transplant was 51 years (range 19-68); 32 patients (57%) were male and 24 patients (43%) were female. A range of haematological malignancies were treated: 20 patients had non-Hodgkin's lymphoma (NHL) (five diffuse large B-cell lymphoma (DLBCL), five follicular lymphoma, two transformed follicular lymphoma, one indolent lymphoma undefined, three mantle cell lymphoma, two small lymphocytic lymphoma, one marginal zone lymphoma, one peripheral T-cell lymphoma), 16 patients had acute myeloid leukaemia (AML), seven patients had multiple myeloma (MM), four patients had Hodgkin's disease (HD), three patients had acute lymphocytic leukaemia (ALL), three patients had myelodysplasia, one patient had chronic lymphocytic leukaemia (CLL), and two patients had myeloproliferative disease (one chronic myeloid leukaemia (CML), one essential thrombocythaemia (ET)). Forty-two of the 56 patients (75%) were in remission or had responsive disease at the time of transplant, 14 patients (25%) were in relapse/ progression, or their disease was refractory or active/ persistent, at the time of transplant ( Table 2 ). The patient population had received a median of three lines of therapy (range 1-11) prior to transplant. Fifteen of the 56 patients (27%) had received a prior autograft and one patient a previous allograft.
The median age of the 55 stem cell donors with these data available was 48 years (range 20-75 years). Donor-recipient sex pairing was female to male in nine patients and female to female in eight patients (the remaining 39 donor-recipient pairs were either male to male, or male to female). All donors were serologically fully matched siblings of the patients. Peripheral blood stem cells alone were donated by 52 (93%) donors. Bone marrow alone was harvested from a further three donors and the remaining donor provided both bone marrow and peripheral blood stem cells. In the 42 patients with data available, a median of 3.85 Â 10 6 CD34 þ cells per kg of the recipient's body weight were infused (range 1.43-13.50).
Results
Engraftment and haematological recovery
Engraftment occurred in 52 of the 56 patients (93%). Engraftment could not be fully confirmed in four cases: two patients died of septic shock on day þ 6 and day þ 22; and two patients died of grade IV aGvHD on day þ 21 and day þ 54 respectively. For the 52 patients with data available, the median time to an absolute neutrophil count of 0.5 Â 10 9 /l was 11 days (range 8-42); filgrastim was used to support neutrophil recovery in 23 (46%) of these patients. Assessable patients receiving FLU/MEL140/CyA had a shorter median time to neutrophil recovery compared to the assessable patients receiving FLU/MEL100/CyA/ MTX (9 days (range 9-14) versus 20.5 days (range 16-42) respectively). However, patients receiving the latter regimen did not receive G-CSF post transplantation. For the 49 patients with platelet recovery data available the median time to a platelet count of 20 Â 10 9 /l was 14 days (range 7-92 days). Patients spent a median of 29 days (range 15-78 days) in hospital. Patients remained on CyA for a median of 5 months (range o1-27 months). The use of MTX was not associated with a significant difference in the length of time on immunosuppression compared to the use of CyA alone (data not shown).
Chimerism Twenty-four of 26 patients (92%) with data available at 3 months post transplant had 495% donor chimerism. Of the two other patients, one had 100% donor chimerism at 6 months and one at 11 months post transplant without the use of DLIs. Two patients received DLI post transplant for relapsed disease (one HD and one AML/CLL). Both responded to DLI but relapsed at a later date.
Graft-versus-host disease
Two patients died prior to engraftment and were not assessable for aGvHD. For patients receiving FLU/ MEL140/CyA, 17 of 33 (52%) suffered aGvHD (two grade I, six grade II, five grade III, three grade IV and one of unknown grade) compared to four of the 20 patients (20%) receiving FLU/MEL100/CyA/MTX (3 grade I, and one grade II). The three patients with grade IV GvHD, and one of the patients with grade III GvHD, died as a consequence of this.
Of the 47 patients surviving for at least 90 days, 23 (49%) developed cGvHD. Of these, 10 had extensive cGvHD, 10 had limited cGvHD and three had cGvHD of unknown extent. For patients receiving FLU/MEL140/CyA, 16 of the 25 (64%) patients developed cGvHD (five limited, eight extensive, three of unknown extent) compared to five of 19 (26%) patients receiving FLU/MEL100/CyA/MTX (three limited, two extensive).
Toxicities
Fourteen patients (25%) experienced CMV reactivation post transplant and four of these went on to develop CMV disease. CMV reactivation was generally treated with ganciclovir. Other reported toxicities included bacterial sepsis (six patients), fungal infection (four patients), cardiac complications (two patients), renal failure (two patients, requiring dialysis in one patient), seizures (three patients), fatal thrombotic thrombocytopenic purpura (one patient), and fatal disseminated varicella infection (one patient). There was no notable difference in the incidence of toxicities based on melphalan dose or immunosuppression used.
Disease response post transplant
Of the 44 patients with 3-month response data available, 34 (77%) were in complete remission (CR) or unconfirmed CRU, five (11%) were in partial remission (PR) or good PR and five (11%) had relapsed or progressed. Of the remaining 12 patients, nine had died by month 3, and three patients did not have a response assessment available at month 3. Twenty-three out of the 44 patients (52%) appeared to show an improvement at month 3 from their disease status at the time of transplant (Table 2) . Thirty-six patients were not in CR at the time of transplant. Of these, 19 patients (53%) were in complete remission at 3 months, five patients (14%) showed an improvement in remission status but were not in CR, three patients (8%) had progressed/relapsed, and the 3-month-response assessment was not available or not applicable (i.e. patient died before month 3) for nine patients (25%). There was no obvious difference in disease response between patients treated with FLU/MEL140/CyA or FLU/MEL100/CyA/MTX (see Table 2 ).
Progression and overall survival
With a median follow-up of 363.5 days (range 7-1158) at the time of data collection, nine patients (16%) had relapsed or progressed (three patients with AML, one with CML, one with MPD, two with MM, one with HD and one with DLBCL) at a median of 3 months (range o1-8 months) post transplant. The overall 100-day mortality rate was 0.16 (95% CI 0.08-0.28) with a 1-year nonrelapse mortality rate of 0.24 (95%CI 0.13-0.38). Seventeen patients (30%) had died at a median of 2 months post transplant (range o1-26 months). Cause of death in each case is listed in Table 2 . Fourteen patients receiving CyA alone as GvHD prophylaxis died during follow-up. Eight of these died within 3 months of transplant before disease response could be assessed, and a further six patients died beyond 3 months. Three patients receiving CyA/MTX as post transplant immunosuppression had died: two had died of disease (at 7 months (AML) and 10 months (DLBCL)) and one patient died prior to disease assessment at 1 month post transplant. For the whole group the 1 year PFS for all patients was 63% (95% CI 50-77%) (Figure 1 ). The median PFS has not yet been reached. The 1 year OS is 70% (95% CI 57-83%). The median OS has not yet been reached (Figure 1) . Thirty-nine patients remain alive of whom 33 are in CR at a median of 19 months post transplant (range 3-38 months).
Discussion
We have collected data on two different RIC regimens, one employing FLU/MEL140/CyA and the other FLU/ MEL100/CyA/MTX.
Although a comparison of the two regimens is complicated by differences in patient demographics, disease status, and the retrospective nature of the nonstudy data collection, it is clear that patients treated with the more aggressive FLU/MEL140/CyA had a higher rate of acute and chronic GvHD, early transplant related death, and progression-free death. However, full donor chimerism was achieved early in the post-transplant period without the need for DLI. Of eight patients with active or resistant disease treated with this regimen, 6 patients showed disease response, with three achieving a CR, suggesting that despite the high-toxicity disease control is good. This is in keeping with other studies employing CyA alone as post transplant immunosuppression. 18 Thus although rapid disease control may be achieved by this regimen, we feel the toxicities would preclude it from routine use except perhaps in those patients with the poorest risk disease.
Disease response appears also to be maintained in patients treated with FLU/MEL100/CyA/MTX, but with the additional benefit of a low incidence of acute and chronic GvHD. Of nine FLU/MEL100/CyA/MTX patients in CR at transplantation seven remained in CR at month 3 and were progression-free at the last follow-up (median of 14 months; range 4-25 months). Although chimerism was not routinely monitored in the patients receiving this regimen due to differences in local practices, rapid donor engraftment is suggested by the responses seen in those patients not in remission at transplantation. Of 11 patients not in remission at transplantation seven had achieved and maintained a CR (including three patients with persistent AML, one with CLL, one LGNHL and two with DLBCL) at a median follow-up of 10 months post transplant (range 3-33 months). Four patients progressed despite transplantation (one with AML, one with MPD, one with CML, and one with DLBCL). No patient had relapsed from a CR achieved post transplantation, suggesting ongoing disease control. These figures are in keeping with other studies employing similar post transplant immunosuppression but with higher doses of melphalan which have been associated with high-transplant toxicity rates especially related to mucositis. 15, 17, 22 Transplant-related mortality was also low in our patients receiving FLU/MEL100/CyA/MTX with only one transplant related death prior to 100 days post transplant. Two further patients died of disease progression at 7 and 10 months (one AML, one DLBCL); neither was in CR at transplant.
The aGvHD incidence and non-relapse mortality are in line with other non-T-cell depleted RIC regimens. 5, 15, 17 Although some of these studies included patients receiving stem cells from unrelated donors comparison has been made with patients receiving matched related transplants where such data are given. In this study, the rate of aGvHD in patients given the FLU/MEL100/CyA/MTX regimen was lower than reported in patients receiving RIC regimens with higher doses of melphalan. 13, 15, 17, 26 These differences may simply be due to chance, although the effect of lowering the melphalan dose and including the additional immunosuppression of MTX cannot be excluded. The use of T-cell depletion has been shown to reduce the risk of GvHD with low transplant related mortality, however, there is possibly a detrimental effect on disease control, especially in patients at high risk of relapse/progression. 7, [25] [26] [27] We have shown that patients transplanted with FLU/ MEL100/CyA/MTX can achieve good disease control with an acceptable level of toxicity. Further studies are required to confirm these findings. 
